Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain Sells 77,705 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 77,705 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $16.39, for a total value of $1,273,584.95. Following the completion of the transaction, the general counsel now directly owns 125,785 shares in the company, valued at $2,061,616.15. The trade was a 38.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Centessa Pharmaceuticals Stock Up 5.1 %

Centessa Pharmaceuticals stock opened at $17.60 on Wednesday. The company has a 50 day moving average of $16.56 and a 200-day moving average of $13.46. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a twelve month low of $6.65 and a twelve month high of $18.97. The stock has a market capitalization of $2.32 billion, a PE ratio of -11.50 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. On average, equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its position in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after acquiring an additional 1,509 shares in the last quarter. Quarry LP grew its stake in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after acquiring an additional 3,108 shares in the last quarter. Sandia Investment Management LP acquired a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $90,000. Finally, Fred Alger Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the second quarter worth $99,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of recent analyst reports. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Jefferies Financial Group lifted their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective for the company. Finally, BMO Capital Markets raised their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.